Amendments to the claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original): A method for treating a patient suffering from a disease selected from the group consisting of: stroke, Alzheimer's disease, fronto-temporal dementias, peripheral neuropathy, Parkinson's disease, dementia with Lewy bodies, Huntington's disease, amyotrophic lateral sclerosis, and multiple sclerosis, said method comprising the step of administering to said patient an effective amount of an LXR modulator in combination with a carrier.

2. (Original): The method as claimed in Claim 1, wherein said LXR modulator is selected from the group consisting of: an LXR agonist and an LXR antagonist.

3. (Original): A method for promoting cholesterol efflux in at least one astroglial cell, said method comprising the step of: contacting said at least one astroglial cell with a cholesterol-efflux-promoting effective amount of an LXR modulator in combination with a carrier.

4. (Original): The method according to Claim 3, wherein said LXR modulator is selected from the group consisting of: an LXR agonist and an LXR antagonist.

5. (Original): A method for treating a patient suffering from a disease or disorder characterised by neuron degeneration, inflammation in the CNS, injury or impaired plasticity, said method comprising the step of administering to said patient an effective amount of an LXR modulator in combination with a carrier.

6. (Original): The method according to Claim 5, wherein said LXR modulator is selected from the group consisting of: an LXR agonist and an LXR antagonist.

7. (Currently amended): The method according to Claim 1 or ~~Claim 4~~, wherein the disease is selected from psychiatric disorders such as schizophrenia and depression.

8. (Currently amended): The method according to Claim 1 ~~or Claim 4~~, wherein the disease is selected from conditions associated with head or spinal cord injury, including trauma.

9. (Currently amended): The method according to Claim 1 ~~any one of Claims 1 to 8~~, wherein the LXR modulator comprises a compound of formula (I)



(I)

wherein:

Ar represents an aryl group; R^1 is –OH, -O-(C_1-C_7)alkyl, -OC(O)-(C_1-C_7)alkyl, -O-(C_1-C_7)heteroalkyl, -OC(O)- (C_1-C_7)heteroalkyl, -CO_2H, -NH_2, -NH(C_1-C_7)alkyl, -N((C_1-C_7)alkyl)$_2$ or –NH-S(O)$_2$-(C_1-C_5)alkyl;

R^2 is (C_1-C_7)alkyl, (C_1-C_7)heteroalkyl, aryl and aryl(C_1-C_7)alkyl;

X^1, X^2, X^3, X^4, X^5 and X^6 are each independently H, (C_1-C_5)alkyl, (C_1-C_5)hetroalkyl, F or Cl, with the proviso that no more than three of X^1 through X^6 are H, (C_1-C_5)alkyl or (C_1-C_5)heteroalkyl; and

Y is –N(R^{12})S(O)$_m$-, -N(R^{12})S(O)$_m$N(R^{13})-, -N(R^{12})C(O)-, –N(R^{12})C(O)N(R^{13})-, -N(R^{12})C(S)- or -N(R^{12})C(O)O-, wherein R12 and R13 are each independently hydrogen, (C_1-C_7)aryl, (C_1-C_7)heteroalkyl, aryl and aryl(C_1-C_7)alkyl, and optionally when Y is –N(R^{12})S(O)$_m$- or -N(R^{12})S(O)$_m$N(R^{13})-, R^{12} forms a five, six or seven-membered ring fused to Ar or to R^2 through covalent attachment to Ar or R^2, respectively. In the above Y groups, the subscript m is an integer of from 1 to 2;

or a pharmaceutically acceptable derivative thereof

10. (Currently amended): The method according to ~~any one of Claims 1 to 8~~ Claim 1, wherein the LXR modulator comprises a compound of formula (II):



II

wherein:

X is OH or NH_2;

p is 0-6;

each R^1 and R^2 are the same or different and are each independently selected from the group consisting of H, C_{1-8}alkyl, C_{1-8}alkoxy and C_{1-8}thioalkyl;

Z is CH or N;

when Z is CH, k is 0-4;

when Z is N, k is 0-3;

each R^3 is the same or different and is independently selected from the group consisting of halo, –OH, C_{1-8}alkyl, C_{2-8}alkenyl, C_{1-8}alkoxy, C_{2-8}alkenyloxy, $-S(O)_aR^6$, $-NR^7R^8$, $-COR^6$, $COOR^6$, $R^{10}COOR^6$, $OR^{10}COOR^6$, $CONR^7R^8$, $-OC(O)R^9$, $-R^{10}NR^7R^8$, $-OR^{10}NR^7R^8$, 5-6 membered heterocycle, nitro, and cyano;

a is 0, 1 or 2;

R^6 is selected from the group consisting of H, C_{1-8}alkyl, C_{1-8}alkoxy and C_{2-8}alkenyl;

each R^7 and R^8 are the same or different and are each independently selected from the group consisting of H, C_{1-8}alkyl, C_{2-8}alkenyl, C_{3-8}alkynyl;

R^9 is selected from the group consisting of H, C_{1-8}alkyl and $-NR^7R^8$;

R^{10} is C_{1-8}alkyl;

n is 2-8;

q is 0 or 1;

R^4 is selected from the group consisting of H, C_{1-8}alkyl, C_{1-8}alkenyl, and alkenyloxy;

Ring A is selected from the group consisting of C_{3-8}cycloalkyl, aryl, 4-8 membered heterocycle, and 5-6 membered heteroaryl;

each ring B is the same or different and is independently selected from the group consisting of C_{3-8}cycloalkyl and aryl:

or a pharmaceutically acceptable derivative thereof.

11. (Currently amended): The method according to ~~any one of Claims 1 to 8~~ Claim 1, wherein the LXR modulator comprises a compound of formula (III):



(III)

wherein:

X is selected from C_1-C_8 alkyl, halo, -OR^{10}, -$NR^{14}R^{15}$, nitro, cyano, -$COOR^{10}$, -COR^{13}, -$OCOR^{13}$, -$CONR^{14}R^{15}$, -$N(R^{17})COR^{13}$, -$N(R^{17})CONR^{14}R^{15}$, -$N(R^{17})COOR^{13}$, -SO_3H, -$SO_2NR^{14}R^{15}$, -$C(=NR^{17})NR^{14}R^{15}$, -$N(R^{17})SO_2R^{16}$, and a 5 or 6-membered heterocyclic group;

or X and an adjacent R^3, taken together with the atoms to which they are bonded, form an alkylenedioxy moiety;

Z is CH, CR^3 or N, wherein when Z is CH or CR^3, k is 0-4 and t is 0 or 1, and when Z is N, k is 0-3 and t is 0;

Y is selected from -O-, -S-, -$N(R^{10})$-, and -$C(R^4)(R^5)$-;

W^1 is selected from C_1-C_6 alkyl, C_3-C_8 cycloalkyl, aryl and Het, wherein said C_1-C_8 alkyl, C_3-C_8 cycloalkyl, Ar and Het are optionally unsubstituted or substituted with one or more groups independently selected from halo, cyano, nitro, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, -C_0-C_6 alkyl-CO_2R^{10}, -C_0-C_6 alkyl-$C(O)SR^{10}$, -C_0-C_6 alkyl-$CONR^{11}R^{12}$, -C_0-C_6 alkyl-COR^{13}, -C_0-C_6 alkyl-$NR^{11}R^{12}$, -C_0-C_6 alkyl-SR^{10}, -C_0-C_6 alkyl-OR^{10}, -C_0-C_6 alkyl-SO_3H, -C_0-C_6 alkyl-$SO_2NR^{11}R^{12}$, -C_0-C_6 alkyl-SO_2R^{10}, -C_0-C_6 alkyl-SOR^{13}, -C_0-C_6 alkyl-$OCOR^{13}$, -C_0-C_6 alkyl-$OC(O)NR^{11}R^{12}$, -C_0-C_6 alkyl-$OC(O)OR^{13}$, -C_0-C_6 alkyl-$NR^{11}C(O)OR^{13}$, -C_0-C_6 alkyl-$NR^{11}C(O)NR^{11}R^{12}$, and -C_0-C_6 alkyl-$NR^{11}COR^{13}$,

where said C_1-C_6 alkyl, is optionally unsubstituted or substituted by one or more halo substituents;

W^2 is selected from H, halo, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, -C_0-C_6 alkyl-$NR^{11}R^{12}$, -C_0-C_6 alkyl-SR^{10}, -C_0-C_6 alkyl-OR^{10}, -C_0-C_6 alkyl-CO_2R^{10}, -C_0-C_6 alkyl-$C(O)SR^{10}$, -C_0-C_6 alkyl-$CONR^{11}R^{12}$, -C_0-C_6 alkyl-COR^{13}, -C_0-C_6 alkyl-$OCOR^{13}$, -C_0-C_6 alkyl-$OCONR^{11}R^{12}$, -C_0-C_6 alkyl-$NR^{11}CONR^{11}R^{12}$, -C_0-C_6 alkyl-$NR^{11}COR^{13}$, -C_0-C_6 alkyl-Het, -C_0-C_6 alkyl-Ar and -C_0-C_6 alkyl-C_3-C_7 cycloalkyl, wherein said C_1-C_6 alkyl is optionally unsubstituted or substituted by one or more halo substituents, and wherein the C_3-C_7 cycloalkyl, Ar and Het moieties of said -C_0-C_6 alkyl-Het, -C_0-C_6 alkyl-Ar and -C_0-C_6 alkyl-C_3-C_7 cycloalkyl are optionally unsubstituted or substituted with one or more groups independently selected from halo, cyano, nitro, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, -C_0-C_6 alkyl-CO_2R^{10}, -C_0-C_6 alkyl-$C(O)SR^{10}$, -C_0-C_6 alkyl-$CONR^{11}R^{12}$, -C_0-C_6 alkyl-COR^{13}, -C_0-C_6 alkyl-$NR^{11}R^{12}$, -C_0-C_6 alkyl-SR^{10}, -C_0-C_6 alkyl-OR^{10}, -C_0-C_6 alkyl-SO_3H, -C_0-C_6 alkyl-$SO_2NR^{11}R^{12}$, -C_0-C_6 alkyl-SO_2R^{10}, -C_0-C_6 alkyl-SOR^{13}, -C_0-C_6 alkyl-$OCOR^{13}$, -C_0-C_6 alkyl-$OC(O)NR^{11}R^{12}$, -C_0-C_6 alkyl-$OC(O)OR^{13}$, -C_0-C_6 alkyl-$NR^{11}C(O)OR^{13}$, -C_0-C_6 alkyl-$NR^{11}C(O)NR^{11}R^{12}$, and -C_0-C_6 alkyl-$NR^{11}COR^{13}$, where said C_1-C_6 alkyl, is optionally unsubstituted or substituted by one or more halo substituents;

W^3 is selected from the group consisting of: H, halo, C_1-C_6 alkyl, -C_0-C_6 alkyl-$NR^{11}R^{12}$, -C_0-C_6 alkyl-SR^{10}, -C_0-C_6 alkyl-OR^{10}, -C_0-C_6 alkyl-CO_2R^{10}, -C_0-C_6 alkyl-$C(O)SR^{10}$, -C_0-C_6 alkyl-$CONR^{11}R^{12}$, -C_0-C_6 alkyl-COR^{13}, -C_0-C_6 alkyl-$OCOR^{13}$, -C_0-C_6 alkyl-$OCONR^{11}R^{12}$, -C_0-C_6 alkyl-$NR^{11}CONR^{11}R^{12}$, -C_0-C_6 alkyl-$NR^{11}COR^{13}$, -C_0-C_6 alkyl-Het, -C_1-C_6 alkyl-Ar and -C_1-C_6 alkyl-C_3-C_7 cycloalkyl, wherein said C_1-C_6 alkyl is optionally unsubstituted or substituted by one or more halo substituents;

Q is selected from C_3-C_8 cycloalkyl, Ar and Het; wherein said C_3-C_8 cycloalkyl, Ar and Het are optionally unsubstituted or substituted with one or more groups independently selected from halo, cyano, nitro, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, -C_0-C_6 alkyl-CO_2R^{10}, -C_0-C_6 alkyl-$C(O)SR^{10}$, -C_0-C_6 alkyl-$CONR^{11}R^{12}$, -C_0-C_6 alkyl-COR^{13}, -C_0-C_6 alkyl-$NR^{11}R^{12}$, -C_0-C_6 alkyl-SR^{10}, -C_0-C_6 alkyl-OR^{10}, -C_0-C_6 alkyl-SO_3H, -C_0-C_6 alkyl-$SO_2NR^{11}R^{12}$, -C_0-C_6 alkyl-SO_2R^{10}, -C_0-C_6 alkyl-SOR^{13}, -C_0-C_6 alkyl-$OCOR^{13}$, -C_0-C_6 alkyl-$OC(O)NR^{11}R^{12}$, -C_0-C_6 alkyl-$OC(O)OR^{13}$, -C_0-C_6 alkyl-$NR^{11}C(O)OR^{13}$,

-C_0-C_6 alkyl-$NR^{11}C(O)NR^{11}R^{12}$, and -C_0-C_6 alkyl-$NR^{11}COR^{13}$, where said C_1-C_6 alkyl is optionally unsubstituted or substituted by one or more halo substituents;

p is 0-8;

n is 2-8;

m is 0 or 1;

q is 0 or 1;

t is 0 or 1;

each R^1 and R^2 are independently selected from H, halo, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, -C_0-C_6 alkyl-$NR^{11}R^{12}$, -C_0-C_6 alkyl-OR^{10}, -C_0-C_6 alkyl-SR^{10}, -C_1-C_6 alkyl-Het, -C_1-C_6 alkyl-Ar and -C_1-C_6 alkyl-C_3-C_7 cycloalkyl, or R^1 and R^2 together with the carbon to which they are attached form a 3-5 membered carbocyclic or heterocyclic ring, wherein said heterocyclic ring contains one, or more heteroatoms selected from N, O, and S, where any of said C_1-C_6 alkyl is optionally unsubstituted or substituted by one or more halo substituents;

each R^3 is the same or different and is independently selected from halo, cyano, nitro, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, -C_0-C_6 alkyl-Ar, -C_0-C_6 alkyl-Het, -C_0-C_6 alkyl-C_3-C_7 cycloalkyl, -C_0-C_6 alkyl-CO_2R^{10}, -C_0-C_6 alkyl-$C(O)SR^{10}$, -C_0-C_6 alkyl-$CONR^{11}R^{12}$, -C_0-C_6 alkyl-COR^{13}, -C_0-C_6 alkyl-$NR^{11}R^{12}$, -C_0-C_6 alkyl-SR^{10}, -C_0-C_6 alkyl-OR^{10}, -C_0-C_6 alkyl-SO_3H, -C_0-C_6 alkyl-$SO_2NR^{11}R^{12}$, -C_0-C_6 alkyl-SO_2R^{10}, -C_0-C_6 alkyl-SOR^{13}, -C_0-C_6 alkyl-$OCOR^{13}$, -C_0-C_6 alkyl-$OC(O)NR^{11}R^{12}$, -C_0-C_6 alkyl-$OC(O)OR^{13}$, -C_0-C_6 alkyl-$NR^{11}C(O)OR^{13}$, -C_0-C_6 alkyl-$NR^{11}C(O)NR^{11}R^{12}$, and -C_0-C_6 alkyl-$NR^{11}COR^{13}$, wherein said C_1-C_6 alkyl is optionally unsubstituted or substituted by one or more halo substituents;

each R^4 and R^5 is independently selected from H, halo, C_1-C_6 alkyl, -C_0-C_6 alkyl-Het, -C_0-C_6 alkyl-Ar and -C_0-C_6 alkyl-C_3-C_7 cycloalkyl;

R^6 and R^7 are each independently selected from H, halo, C_1-C_6 alkyl, -C_0-C_6 alkyl-Het, -C_0-C_6 alkyl-Ar and -C_0-C_6 alkyl-C_3-C_7 cycloalkyl;

R^8 and R^9 are each independently selected from H, halo, C_1-C_6 alkyl, -C_0-C_6 alkyl-Het, -C_0-C_6 alkyl-Ar and -C_0-C_6 alkyl-C_3-C_7 cycloalkyl;

R^{10} is selected from H, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, -C_0-C_6 alkyl-Ar, -C_0-C_6 alkyl-Het and -C_0-C_6 alkyl-C_3-C_7 cycloalkyl;

each R^{11} and each R^{12} are independently selected from H, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, -C_0-C_6 alkyl-Ar, -C_0-C_6 alkyl-Het and -C_0-C_6 alkyl-C_3-C_7 cycloalkyl, or R^{11} and R^{12} together with the nitrogen to which they are attached form a 4-7 membered

heterocyclic ring which optionally contains one or more additional heteroatoms selected from N, O, and S;

R^{13} is selected from C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, -C_0-C_6 alkyl-Ar, -C_0-C_6 alkyl-Het and -C_0-C_6 alkyl-C_3-C_7 cycloalkyl;

R^{14} and R^{15} are each independently selected from H, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, -C_0-C_6 alkyl-Ar, -C_0-C_6 alkyl-Het, -C_0-C_6 alkyl-C_3-C_7 cycloalkyl, -C_0-C_6 alkyl-O-Ar, -C_0-C_6 alkyl-O-Het, -C_0-C_6 alkyl-O-C_3-C_7 cycloalkyl, -C_0-C_6 alkyl-$S(O)_x$-C_1-C_6 alkyl, -C_0-C_6 alkyl-$S(O)_x$-Ar, -C_0-C_6 alkyl-$S(O)_x$-Het, -C_0-C_6 alkyl-$S(O)_x$-C_3-C_7 cycloalkyl, -C_0-C_6 alkyl-NH-Het, -C_0-C_6 alkyl-NH-C_3-C_7 cycloalkyl, -C_0-C_6 alkyl-N(C_1-C_4 alkyl)-Ar, -C_0-C_6 alkyl-N(C_1-C_4 alkyl)-Het, -C_0-C_6 alkyl-N(C_1-C_4 alkyl)-C_3-C_7 cycloalkyl, -C_0-C_6 alkyl-Ar, -C_0-C_6 alkyl-Het and -C_0-C_6 alkyl-C_3-C_7 cycloalkyl, where x is 0, 1 or 2, or R^{14} and R^{15}, together with the nitrogen to which they are attached, form a 4-7 membered heterocyclic ring which optionally contains one or more additional heteroatoms selected from N, O, and S, wherein said C_1-C_6 alkyl is optionally substituted by one or more of the substituents independently selected from the group halo, -OH, -SH, $-NH_2$, -NH(unsubstituted C_1-C_6 alkyl), -N(unsubstituted C_1-C_6 alkyl)(unsubstituted C_1-C_6 alkyl), unsubstituted -OC_1-C_6 alkyl, $-CO_2H$, $-CO_2$(unsubstituted C_1-C_6 alkyl), $-CONH_2$, -CONH(unsubstituted C_1-C_6 alkyl), -CON(unsubstituted C_1-C_6 alkyl)(unsubstituted C_1-C_6 alkyl), $-SO_3H$, $-SO_2NH_2$, $-SO_2$NH(unsubstituted C_1-C_6 alkyl) and $-SO_2$N(unsubstituted C_1-C_6 alkyl)(unsubstituted C_1-C_6 alkyl);

R^{16} is C_1-C_6 alkyl, -C_0-C_6 alkyl-Ar or -C_0-C_6 alkyl-Het; and

R^{17} is H, C_1-C_6 alkyl, -C_0-C_6 alkyl-Ar or -C_0-C_6 alkyl-Het;

or a pharmaceutically acceptable salt or solvate thereof.

12. (Currently amended): The method according to ~~any one of Claims 1 to 8~~ Claim 1, wherein the LXR modulator comprises a compound of formula (IV):



(IV)

wherein:

X is CH or N;

Y is $N(R^{10})$, O, or S, wherein t is 0 or 1 when Y is $N(R^{10})$ or O, and t is 0 when Y is S;

U is selected from halo, $-OR^{10}$, $-NR^{14}R^{15}$, nitro, cyano, $-COOR^{10}$, $-COR^{13}$, $-OCOR^{13}$, $-CONR^{14}R^{15}$, $-N(R^{14})COR^{13}$, $-SO_3H$, $-SO_2NR^{14}R^{15}$, $-C(=NR^{17})NR^{14}R^{15}$, $-N(R^{14})SO_2R^{16}$, and a 5 or 6-membered heterocyclic group;

A is a phenyl fused ring moiety or a pyridyl fused ring moiety, wherein when A is a phenyl ring moiety, k is 0-3 and t is 0 or 1 and when A is a pyridyl ring moiety, k is 0-2 and t is 0;

W^1 is selected from C_3-C_8 cycloalkyl, aryl and Het, wherein said C_3-C_8 cycloalkyl, Ar and Het are optionally unsubstituted or substituted with one or more groups independently selected from halo, cyano, nitro, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, $-C_0$-C_6 alkyl-CO_2R^{10}, $-C_0$-C_6 alkyl-$C(O)SR^{10}$, $-C_0$-C_6 alkyl-$CONR^{11}R^{12}$, $-C_0$-C_6 alkyl-COR^{13}, $-C_0$-C_6 alkyl-$NR^{11}R^{12}$, $-C_0$-C_6 alkyl-SR^{10}, $-C_0$-C_6 alkyl-OR^{10}, $-C_0$-C_6 alkyl-SO_3H, $-C_0$-C_6 alkyl-$SO_2NR^{11}R^{12}$, $-C_0$-C_6 alkyl-SO_2R^{10}, $-C_0$-C_6 alkyl-SOR^{13}, $-C_0$-C_6 alkyl-$OCOR^{13}$, $-C_0$-C_6 alkyl-$OC(O)NR^{11}R^{12}$, $-C_0$-C_6 alkyl-$OC(O)OR^{13}$, $-C_0$-C_6 alkyl-$NR^{11}C(O)OR^{13}$, $-C_0$-C_6 alkyl-$NR^{11}C(O)NR^{11}R^{12}$, and $-C_0$-C_6 alkyl-$NR^{11}COR^{13}$, where said C_1-C_6 alkyl, is optionally unsubstituted or substituted by one or more halo substituents;

W^2 is selected from H, halo, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $-C_0$-C_6 alkyl-$NR^{11}R^{12}$, $-C_0$-C_6 alkyl-SR^{10}, $-C_0$-C_6 alkyl-OR^{10}, $-C_0$-C_6 alkyl-CO_2R^{10}, $-C_0$-C_6 alkyl-$C(O)SR^{10}$, $-C_0$-C_6 alkyl-$CONR^{11}R^{12}$, $-C_0$-C_6 alkyl-COR^{13}, $-C_0$-C_6 alkyl-$OCOR^{13}$, $-C_0$-C_6 alkyl-$OCONR^{11}R^{12}$, $-C_0$-C_6 alkyl-$NR^{11}CONR^{11}R^{12}$, $-C_0$-C_6 alkyl-$NR^{11}COR^{13}$, $-C_0$-C_6 alkyl-Het, $-C_0$-C_6 alkyl-Ar and

-C_0-C_6 alkyl-C_3-C_7 cycloalkyl, wherein said C_1-C_6 alkyl is optionally unsubstituted or substituted by one or more halo substituents, and wherein the C_3-C_7 cycloalkyl, Ar and Het moieties of said -C_0-C_6 alkyl-Het, -C_0-C_6 alkyl-Ar and -C_0-C_6 alkyl-C_3-C_7 cycloalkyl are optionally unsubstituted or substituted with one or more groups independently selected from halo, cyano, nitro, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, -C_0-C_6 alkyl-CO_2R^{10}, -C_0-C_6 alkyl-$C(O)SR^{10}$, -C_0-C_6 alkyl-$CONR^{11}R^{12}$, -C_0-C_6 alkyl-COR^{13}, -C_0-C_6 alkyl-$NR^{11}R^{12}$, -C_0-C_6 alkyl-SR^{10}, -C_0-C_6 alkyl-OR^{10}, -C_0-C_6 alkyl-SO_3H, -C_0-C_6 alkyl-$SO_2NR^{11}R^{12}$, -C_0-C_6 alkyl-SO_2R^{10}, -C_0-C_6 alkyl-SOR^{13}, -C_0-C_6 alkyl-$OCOR^{13}$, -C_0-C_6 alkyl-$OC(O)NR^{11}R^{12}$, -C_0-C_6 alkyl-$OC(O)OR^{13}$, -C_0-C_6 alkyl-$NR^{11}C(O)OR^{13}$, -C_0-C_6 alkyl-$NR^{11}C(O)NR^{11}R^{12}$, and -C_0-C_6 alkyl-$NR^{11}COR^{13}$, where said C_1-C_6 alkyl, is optionally unsubstituted or substituted by one or more halo substituents;

W^3 is selected from the group consisting of: H, halo, C_1-C_6 alkyl, -C_0-C_6 alkyl-$NR^{11}R^{12}$, -C_0-C_6 alkyl-SR^{10}, -C_0-C_6 alkyl-OR^{10}, -C_0-C_6 alkyl-CO_2R^{10}, -C_0-C_6 alkyl-$C(O)SR^{10}$, -C_0-C_6 alkyl-$CONR^{11}R^{12}$, -C_0-C_6 alkyl-COR^{13}, -C_0-C_6 alkyl-$OCOR^{13}$, -C_0-C_6 alkyl-$OCONR^{11}R^{12}$, -C_0-C_6 alkyl-$NR^{11}CONR^{11}R^{12}$, -C_0-C_6 alkyl-$NR^{11}COR^{13}$, -C_0-C_6 alkyl-Het, -C_1-C_6 alkyl-Ar and -C_1-C_6 alkyl-C_3-C_7 cycloalkyl, wherein said C_1-C_6 alkyl is optionally unsubstituted or substituted by one or more halo substituents;

Q is selected from C_3-C_8 cycloalkyl, Ar and Het; wherein said C_3-C_8 cycloalkyl, Ar and Het are optionally unsubstituted or substituted with one or more groups independently selected from halo, cyano, nitro, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, -C_0-C_6 alkyl-CO_2R^{10}, -C_0-C_6 alkyl-$C(O)SR^{10}$, -C_0-C_6 alkyl-$CONR^{11}R^{12}$, -C_0-C_6 alkyl-COR^{13}, -C_0-C_6 alkyl-$NR^{11}R^{12}$, -C_0-C_6 alkyl-SR^{10}, -C_0-C_6 alkyl-OR^{10}, -C_0-C_6 alkyl-SO_3H, -C_0-C_6 alkyl-$SO_2NR^{11}R^{12}$, -C_0-C_6 alkyl-SO_2R^{10}, -C_0-C_6 alkyl-SOR^{13}, -C_0-C_6 alkyl-$OCOR^{13}$, -C_0-C_6 alkyl-$OC(O)NR^{11}R^{12}$, -C_0-C_6 alkyl-$OC(O)OR^{13}$, -C_0-C_6 alkyl-$NR^{11}C(O)OR^{13}$, -C_0-C_6 alkyl-$NR^{11}C(O)NR^{11}R^{12}$, and -C_0-C_6 alkyl-$NR^{11}COR^{13}$, where said C_1-C_6 alkyl is optionally unsubstituted or substituted by one or more halo substituents;

p is 0-8;

n is 2-8;

m is 0 or 1;

q is 0 or 1;

t is 0 or 1;

each R^1 and R^2 are independently selected from H, halo, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, -C_0-C_6 alkyl-$NR^{11}R^{12}$, -C_0-C_6 alkyl-OR^{10}, -C_0-C_6 alkyl-SR^{10}, -C_1-C_6 alkyl-Het, -C_1-C_6 alkyl-Ar and -C_1-C_6 alkyl-C_3-C_7 cycloalkyl, or R^1 and R^2 together with the carbon to which they are attached form a 3-5 membered carbocyclic or heterocyclic ring, wherein said heterocyclic ring contains one, or more heteroatoms selected from N, O, and S, where said C_1-C_6 alkyl is optionally unsubstituted or substituted by one or more halo substituents;

each R^3 is the same or different and is independently selected from halo, cyano, nitro, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, -C_0-C_6 alkyl-Ar, -C_0-C_6 alkyl-Het, -C_0-C_6 alkyl-C_3-C_7 cycloalkyl, -C_0-C_6 alkyl-CO_2R^{10}, -C_0-C_6 alkyl-$C(O)SR^{10}$, -C_0-C_6 alkyl-$CONR^{11}R^{12}$, -C_0-C_6 alkyl-COR^{13}, -C_0-C_6 alkyl-$NR^{11}R^{12}$, -C_0-C_6 alkyl-SR^{10}, -C_0-C_6 alkyl-OR^{10}, -C_0-C_6 alkyl-SO_3H, -C_0-C_6 alkyl-$SO_2NR^{11}R^{12}$, -C_0-C_6 alkyl-SO_2R^{10}, -C_0-C_6 alkyl-SOR^{13}, -C_0-C_6 alkyl-$OCOR^{13}$, -C_0-C_6 alkyl-$OC(O)NR^{11}R^{12}$, -C_0-C_6 alkyl-$OC(O)OR^{13}$, -C_0-C_6 alkyl-$NR^{11}C(O)OR^{13}$, -C_0-C_6 alkyl-$NR^{11}C(O)NR^{11}R^{12}$, and -C_0-C_6 alkyl-$NR^{11}COR^{13}$, wherein said C_1-C_6 alkyl is optionally unsubstituted or substituted by one or more halo substituents;

each R^4 and R^5 is independently selected from H, halo, C_1-C_6 alkyl, -C_0-C_6 alkyl-Het, -C_0-C_6 alkyl-Ar and -C_0-C_6 alkyl-C_3-C_7 cycloalkyl;

R^6 and R^7 are each independently selected from H, halo, C_1-C_6 alkyl, -C_0-C_6 alkyl-Het, -C_0-C_6 alkyl-Ar and -C_0-C_6 alkyl-C_3-C_7 cycloalkyl;

R^8 and R^9 are each independently selected from H, halo, C_1-C_6 alkyl, -C_0-C_6 alkyl-Het, -C_0-C_6 alkyl-Ar and -C_0-C_6 alkyl-C_3-C_7 cycloalkyl;

R^{10} is selected from H, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, -C_0-C_6 alkyl-Ar, -C_0-C_6 alkyl-Het and -C_0-C_6 alkyl-C_3-C_7 cycloalkyl;

each R^{11} and each R^{12} are independently selected from H, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, -C_0-C_6 alkyl-Ar, -C_0-C_6 alkyl-Het and -C_0-C_6 alkyl-C_3-C_7 cycloalkyl, or R^{11} and R^{12} together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring which optionally contains one or more additional heteroatoms selected from N, O, and S;

R^{13} is selected from C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, -C_0-C_6 alkyl-Ar, -C_0-C_6 alkyl-Het and -C_0-C_6 alkyl-C_3-C_7 cycloalkyl;

R^{14} and R^{15} are each independently selected from H, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, -C_0-C_6 alkyl-Ar, -C_0-C_6 alkyl-Het, -C_0-C_6 alkyl-C_3-C_7 cycloalkyl, -C_0-C_6 alkyl-O-Ar, -C_0-C_6 alkyl-O-Het, -C_0-C_6 alkyl-O-C_3-C_7 cycloalkyl,

-C_0-C_6 alkyl-$S(O)_x$-C_1-C_6 alkyl, -C_0-C_6 alkyl-$S(O)_x$-Ar, -C_0-C_6 alkyl-$S(O)_x$-Het, -C_0-C_6 alkyl-$S(O)_x$-C_3-C_7 cycloalkyl, -C_0-C_6 alkyl-NH-Ar, -C_0-C_6 alkyl-NH-Het, -C_0-C_6 alkyl-NH-C_3-C_7 cycloalkyl, -C_0-C_6 alkyl-N(C_1-C_4 alkyl)-Ar, -C_0-C_6 alkyl-N(C_1-C_4 alkyl)-Het, -C_0-C_6 alkyl-N(C_1-C_4 alkyl)-C_3-C_7 cycloalkyl, -C_0-C_6 alkyl-Ar, -C_0-C_6 alkyl-Het and -C_0-C_6 alkyl-C_3-C_7 cycloalkyl, where x is 0, 1 or 2, or R^{14} and R^{15}, together with the nitrogen to which they are attached, form a 4-7 membered heterocyclic ring which optionally contains one or more additional heteroatoms selected from N, O, and S, wherein said C_1-C_6 alkyl is optionally substituted by one or more of the substituents independently selected from the group halo, -OH, -SH, $-NH_2$, -NH(unsubstituted C_1-C_6 alkyl), -N(unsubstituted C_1-C_6 alkyl)(unsubstituted C_1-C_6 alkyl), unsubstituted -OC_1-C_6 alkyl, $-CO_2H$, $-CO_2$(unsubstituted C_1-C_6 alkyl), $-CONH_2$, -CONH(unsubstituted C_1-C_6 alkyl), -CON(unsubstituted C_1-C_6 alkyl)(unsubstituted C_1-C_6 alkyl), $-SO_3H$, $-SO_2NH_2$, $-SO_2NH$(unsubstituted C_1-C_6 alkyl) and $-SO_2N$(unsubstituted C_1-C_6 alkyl)(unsubstituted C_1-C_6 alkyl);

R^{16} is C_1-C_6 alkyl, -C_0-C_6 alkyl-Ar or -C_0-C_6 alkyl-Het; and

R^{17} is H, C_1-C_6 alkyl, -C_0-C_6 alkyl-Ar or -C_0-C_6 alkyl-Het;

or a pharmaceutically acceptable salt or solvate thereof.

13. (Currently amended): The method according to ~~any one of Claims 1 to 8~~ Claim 1, wherein the LXR modulator comprises a compound of formula (V):



(V)

or a pharmaceutically acceptable derivative thereof.

14. (Currently Amended): The method according to ~~any one of Claims 1 to 8~~ Claim 1, wherein the LXR modulator comprises a compound of formula (VI):



(VI)

or a pharmaceutically acceptable derivative thereof.

15. (Currently Amended): The method according to ~~any one of Claims 1-14~~ Claim 1, wherein the LXR modulator is an LXR agonist.

16-27 (Cancelled).